Details for Patent: 12,054,498
Which drugs does patent 12,054,498 protect, and when does it expire?
Patent 12,054,498 protects JIDEYTRO and is included in one NDA.
This patent has nineteen patent family members in thirteen countries.
Summary for Patent: 12,054,498
| Title: | Heteroaromatic macrocyclic ether chemotherapeutic agents |
| Abstract: | Disclosed are heterocyclic heteroaromatic macrocyclic ether compounds of Formula (I): pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. The disclosure further relates to methods of treating or preventing cancer using the heterocyclic heteroaromatic macrocyclic ether compounds, pharmaceutically acceptable salts of the compounds and pharmaceutical compositions thereof. |
| Inventor(s): | Joshua Courtney Horan, Xinxing Tang, Scot Richard Mente, Henry Efrem Pelish, Matthew D. Shair, Anupong Tangpeerachaikul |
| Assignee: | Pharmaresources Co Ltd , Nuvalent Inc |
| Application Number: | US17/834,135 |
|
Patent Claim Types: see list of patent claims | Use; Composition; |
Drugs Protected by US Patent 12,054,498
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-001 | Jul 22, 2026 | RX | Yes | No | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE RECEIVED AT LEAST ONE PRIOR ROS1 KINASE INHIBITOR | ⤷ Start Trial | ||||
| Nuvalent | JIDEYTRO | zidesamtinib | TABLET;ORAL | 220185-002 | Jul 22, 2026 | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | TREATMENT OF ADULT PATIENTS WITH LOCALLY ADVANCED OR METASTATIC ROS1-POSITIVE NON-SMALL CELL LUNG CANCER (NSCLC) WHO HAVE RECEIVED AT LEAST ONE PRIOR ROS1 KINASE INHIBITOR | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 12,054,498
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2021268664 | ⤷ Start Trial | |||
| Brazil | 112022022535 | ⤷ Start Trial | |||
| Canada | 3179700 | ⤷ Start Trial | |||
| Chile | 2022003045 | ⤷ Start Trial | |||
| China | 115916754 | ⤷ Start Trial | |||
| European Patent Office | 4146626 | ⤷ Start Trial | |||
| Israel | 297832 | ⤷ Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
